- There have been reports of heart inflammation issues with teens and young adults after receiving an mRNA COVID-19 vaccines
- The CDC says the condition often goes away without complications and can be caused by a variety of viruses
- Authorities say they did not find more cases of the condition than would be expected in the population, but felt healthcare providers should be aware
The CDC’s Advisory Committee on Immunization Practices in a statement dated May 17 said it had investigated reports that a few young vaccine recipients, predominantly adolescents and young adults, and predominantly male, developed myocarditis, an inflammation of the heart muscle.
The condition often goes away without complications and can be caused by a variety of viruses, the CDC group said.
CDC monitoring systems had not found more cases than would be expected in the population, but members of the committee on vaccinations felt that healthcare providers should be made aware of the reports of the “potential adverse event”, the committee said in the statement.
It did not say how many people had been affected and recommended further investigation.
The CDC said the cases typically occurred within four days after receiving an mRNA vaccine.
It did not specify which brand of vaccines.
The United States has given emergency authorisation to two mRNA vaccines, from Moderna and Pfizer.
Earlier this month, the US authorised the Pfizer vaccine for children aged 12 to 15.
UK confident Pfizer vaccine effective against India variant
A double dose of COVID-19 vaccines is almost as effective against the fast-spreading variant of the coronavirus first identified in India as it is against Britain’s dominant strain, UK health officials said on Saturday.
The UK’s Health Secretary said the data was ground-breaking and he was increasingly hopeful that the government would be able to lift more COVID-19 restrictions next month.
A study by Public Health England (PHE) found the Pfizer-BioNTech vaccine was 88 per cent effective against symptomatic disease from the B.1.617.2 variant two weeks after the second dose.
That compared with 93 per cent effectiveness against the B.1.1.7 strain — known as the Kent strain — which is Britain’s dominant COVID variant.
Two doses of the AstraZeneca vaccine were 60 per cent effective against symptomatic disease from the Indian variant compared with 66 per cent effectiveness against the Kent variant, PHE said.
“I’m increasingly confident that we’re on track for the roadmap, because this data shows that the vaccine, after two doses, works just as effectively [against the Indian variant],” Health Secretary Matt Hancock told media.
Data published on Saturday showed new COVID cases reported in Britain rose by 10.5 per cent in the seven days to May 22, although it remained a fraction of levels seen earlier this year.
PHE said the first dose of both vaccines was 33 per cent effective against symptomatic disease from B.1.617.2 after three weeks, lower than its 50 per cent effectiveness against B.1.1.7.
Mr Hancock said that showed that getting both doses of the vaccine was “absolutely vital”.